CCR2 and CCR5 Antagonists for Neurodegeneration

CCR2 and CCR5 Antagonists for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CCR2 and CCR5 Antagonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PF-04136309</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">CCX872</td>
<td>ChemoCentryx</td>
</tr>
<tr>
<td class="label">RS504393</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">IN4</td>
<td>Incyte</td>
</tr>
<tr>
<td class="label">MLN1202</td>
<td>Millennium</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Maraviroc</td>
<td>Pfizer/ViiV</td>
</tr>
<tr>
<td class="label">Vicriviroc</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">Aplaviroc</td>
<td>GSK</td>
</tr>
<tr>
<td class="label">Cenicriviroc</td>
<td>Tobira/Allergan</td>
</tr>
</table>

Ccr2 And Ccr5 Antagonists For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Chemokine receptors CCR2 and CCR5 play crucial roles in neuroinflammation by mediating monocyte/microglia recruitment to the central nervous system. CCR2/CCR5 antagonists represent a promising therapeutic approach for reducing harmful neuroinflammation while preserving beneficial immune surveillance. [@pmida]

CCR2 and CCR5 Antagonists for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CCR2 and CCR5 Antagonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PF-04136309</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">CCX872</td>
<td>ChemoCentryx</td>
</tr>
<tr>
<td class="label">RS504393</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">IN4</td>
<td>Incyte</td>
</tr>
<tr>
<td class="label">MLN1202</td>
<td>Millennium</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Maraviroc</td>
<td>Pfizer/ViiV</td>
</tr>
<tr>
<td class="label">Vicriviroc</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">Aplaviroc</td>
<td>GSK</td>
</tr>
<tr>
<td class="label">Cenicriviroc</td>
<td>Tobira/Allergan</td>
</tr>
</table>

Ccr2 And Ccr5 Antagonists For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Chemokine receptors CCR2 and CCR5 play crucial roles in neuroinflammation by mediating monocyte/microglia recruitment to the central nervous system. CCR2/CCR5 antagonists represent a promising therapeutic approach for reducing harmful neuroinflammation while preserving beneficial immune surveillance. [@pmida]

Molecular Mechanism

CCR2 Signaling

• CCR2 is expressed on monocytes, macrophages, and [microglia](/entities/microglia)
• Ligands include CCL2 (MCP-1), CCL7, CCL8, CCL13
• Activation triggers monocyte recruitment to sites of inflammation
• In neurodegeneration, excessive CCL2-CCR2 signaling drives harmful microglial activation

CCR5 Signaling

• CCR5 is expressed on [microglia](/cell-types/microglia-neuroinflammation), [neurons](/entities/neurons), and [astrocytes](/entities/astrocytes)
• Ligands include CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES)
• Mediates neurotoxic inflammation in AD, PD, HD, and ALS
• Contributes to leukocyte recruitment across the [blood-brain barrier](/entities/blood-brain-barrier)

Antagonist Mechanisms

• Block chemokine binding to prevent receptor activation
• Reduce microglial activation and proliferation
• Decrease pro-inflammatory cytokine production
• Preserve neuroprotective immune functions

Disease Applications

Alzheimer's Disease

• Reduces microglial recruitment around amyloid plaques
• Decreases CCL2/CCR2-mediated neuroinflammation
• May improve cognitive function
• Evidence from [APP](/entities/app-protein)/PS1 mouse models

Parkinson's Disease

• Blocks dopaminergic neuron loss
• Reduces microglial activation in substantia nigra
• Decreases [α-synuclein](/proteins/alpha-synuclein)-induced inflammation
• Protective in MPTP and 6-OHDA models

Huntington's Disease

• Reduces mutant [huntingtin](/proteins/huntingtin-protein)-induced neuroinflammation
• Decreases microglia activation
• Improves motor function in R6/2 mice
• May slow disease progression

Amyotrophic Lateral Sclerosis

• Reduces microglia-mediated motor neuron injury
• Blocks monocyte infiltration
• May extend survival in SOD1 models

Therapeutic Agents

CCR2 Antagonists

CCR5 Antagonists

Dual CCR2/CCR5 Antagonists

• Cenicriviroc (CVC) - most advanced for neurodegeneration
• Blocks both pathways with single agent
• Currently in Phase II trials for AD

Clinical Evidence

Preclinical

• CCR2 knockout mice show reduced amyloid deposition
• CCR5 deficiency improves memory in AD models
• Dual antagonism more effective than single receptor blockade

Clinical

• Cenicriviroc Phase II trial in AD (NCT02328872)
• Maraviroc being repurposed for AD (NCT01091614)
• Ongoing trials in MS and ALS

Dosing and Administration

CCR2 Antagonists

• PF-04136309: 500mg oral BID (under investigation)
• CCX872: Dosing under investigation

CCR5 Antagonists

• Maraviroc: 300mg oral BID (HIV dose, potential CNS dose TBD)
• Cenicriviroc: 500mg daily

Adverse Effects

Common

• Headache
• Nausea
• Fatigue
• Elevated liver enzymes (some agents)

Considerations

• Drug-drug interactions (maraviroc)
• Immune suppression risk
• Long-term safety in CNS diseases unknown

Biomarkers

• CCL2 levels in CSF
• Microglial imaging (TSPO PET)
• Peripheral monocyte counts
• Inflammatory cytokines (IL-1β, IL-6, TNF-α)

Research Directions

• Brain-penetrant antagonists
• Biomarker-driven patient selection
• Combination with disease-modifying therapies
• Prevention trials in at-risk individuals

See Also

• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [CCL2/MCP-1](/proteins/ccl2-protein)
• [Microglial Modulation](/therapeutics/microglia-modulation-therapy-neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

Background

The study of Ccr2 And Ccr5 Antagonists For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;